These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

160 related items for PubMed ID: 22447885

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type.
    Quartier P, Taupin P, Bourdeaut F, Lemelle I, Pillet P, Bost M, Sibilia J, Koné-Paut I, Gandon-Laloum S, LeBideau M, Bader-Meunier B, Mouy R, Debré M, Landais P, Prieur AM.
    Arthritis Rheum; 2003 Apr; 48(4):1093-101. PubMed ID: 12687553
    [Abstract] [Full Text] [Related]

  • 6. Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry.
    Horneff G, De Bock F, Foeldvari I, Girschick HJ, Michels H, Moebius D, Schmeling H, German and Austrian Paediatric Rheumatology Collaborative Study Group.
    Ann Rheum Dis; 2009 Apr; 68(4):519-25. PubMed ID: 18413440
    [Abstract] [Full Text] [Related]

  • 7. Safety and efficacy of etanercept in a cohort of patients with juvenile idiopathic arthritis under 4 years of age.
    Bracaglia C, Buonuomo PS, Tozzi AE, Pardeo M, Nicolai R, Campana A, Insalaco A, Cortis E, DE Benedetti F.
    J Rheumatol; 2012 Jun; 39(6):1287-90. PubMed ID: 22589254
    [Abstract] [Full Text] [Related]

  • 8. Focus on adverse events of tumour necrosis factor alpha blockade in juvenile idiopathic arthritis in an open monocentric long-term prospective study of 163 patients.
    Gerloni V, Pontikaki I, Gattinara M, Fantini F.
    Ann Rheum Dis; 2008 Aug; 67(8):1145-52. PubMed ID: 17981916
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Improvement in health-related quality of life for children with juvenile idiopathic arthritis after start of treatment with etanercept.
    Klotsche J, Minden K, Thon A, Ganser G, Urban A, Horneff G.
    Arthritis Care Res (Hoboken); 2014 Feb; 66(2):253-62. PubMed ID: 23983081
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Ongoing disease activity and changing categories in a long-term nordic cohort study of juvenile idiopathic arthritis.
    Nordal E, Zak M, Aalto K, Berntson L, Fasth A, Herlin T, Lahdenne P, Nielsen S, Straume B, Rygg M, Nordic Study Group of Pediatric Rheumatology.
    Arthritis Rheum; 2011 Sep; 63(9):2809-18. PubMed ID: 21560116
    [Abstract] [Full Text] [Related]

  • 16. Factors associated with achievement of inactive disease in children with juvenile idiopathic arthritis treated with etanercept.
    Solari N, Palmisani E, Consolaro A, Pistorio A, Viola S, Buoncompagni A, Gattorno M, Picco P, Ruperto N, Malattia C, Martini A, Ravelli A.
    J Rheumatol; 2013 Feb; 40(2):192-200. PubMed ID: 23204218
    [Abstract] [Full Text] [Related]

  • 17. Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis.
    Lovell DJ, Reiff A, Jones OY, Schneider R, Nocton J, Stein LD, Gedalia A, Ilowite NT, Wallace CA, Whitmore JB, White B, Giannini EH, Pediatric Rheumatology Collaborative Study Group.
    Arthritis Rheum; 2006 Jun; 54(6):1987-94. PubMed ID: 16732547
    [Abstract] [Full Text] [Related]

  • 18. Factors associated with treatment response to etanercept in juvenile idiopathic arthritis.
    Otten MH, Prince FH, Armbrust W, ten Cate R, Hoppenreijs EP, Twilt M, Koopman-Keemink Y, Gorter SL, Dolman KM, Swart JF, van den Berg JM, Wulffraat NM, van Rossum MA, van Suijlekom-Smit LW.
    JAMA; 2011 Dec 07; 306(21):2340-7. PubMed ID: 22056397
    [Abstract] [Full Text] [Related]

  • 19. A comparison of response criteria to evaluate therapeutic response in patients with juvenile idiopathic arthritis treated with methotrexate and/or anti-tumor necrosis factor alpha agents.
    Lurati A, Pontikaki I, Teruzzi B, Desiati F, Gerloni V, Gattinara M, Cimaz R, Fantini F.
    Arthritis Rheum; 2006 May 07; 54(5):1602-7. PubMed ID: 16646003
    [Abstract] [Full Text] [Related]

  • 20. Effectiveness and safety of a second and third biological agent after failing etanercept in juvenile idiopathic arthritis: results from the Dutch National ABC Register.
    Otten MH, Prince FH, Anink J, Ten Cate R, Hoppenreijs EP, Armbrust W, Koopman-Keemink Y, van Pelt PA, Kamphuis S, Gorter SL, Dolman KM, Swart JF, van den Berg JM, Wulffraat NM, van Rossum MA, van Suijlekom-Smit LW.
    Ann Rheum Dis; 2013 May 07; 72(5):721-7. PubMed ID: 22730374
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.